Patents Assigned to iNtRON Biotechnology, Inc.
  • Patent number: 9334513
    Abstract: The present invention relates to a method for biologically producing heme-iron through microorganism cultivation, and to an iron supplementing composition containing the heme-iron produced by the same. The present invention provides a method for biologically producing heme-iron through microorganism cultivation, making it possible to economically produce heme-iron or heme-iron preparations which can be safely used as an iron supplement.
    Type: Grant
    Filed: September 2, 2009
    Date of Patent: May 10, 2016
    Assignees: Catholic University Industry Academic Cooperation Foundation, iNtRON Biotechnology, Inc.
    Inventor: Pil Kim
  • Patent number: 9309498
    Abstract: The present invention relates to a bacteriophage having bactericidal activity against Actinobacillus pleuropneumoniae. Bacteriophage PA1? can infect Actinobacillus pleuropneumoniae and kill the same bacteria and is characterized by the genome of 34,553 by represented by SEQ ID NO: 1.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: April 12, 2016
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Ji Hoon Kim, Tae Gyu Kim, Seong Jun Yoon, Soo Youn Jun, Sang Hyeon Kang, Jung Min Kim, Shuk Ho Kim
  • Publication number: 20160051707
    Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent, particularly a metal oxide nanoparticle-based T1-T2 dual-mode MRI contrast agent that can be used not only as a T1 MRI contrast agent but also as a T2 MRI contrast agent, and a method for producing the same. The metal oxide nanoparticle-based T1-T2 dual-mode MRI contrast agent can provide more accurate and detailed information associated with disease than single MRI contrast agent by the beneficial contrast effects in both T1 imaging with high tissue resolution and T2 imaging with high feasibility on detection of a lesion.
    Type: Application
    Filed: April 5, 2013
    Publication date: February 25, 2016
    Applicant: INTRON BIOTECHNOLOGY, INC.
    Inventors: Kwang Yeol Lee, Min Sik Kim, Taek Hoon Kim, Ngoc Phan Vu
  • Patent number: 9211309
    Abstract: The present invention relates to a composition comprising EK99P-1, a bacteriophage isolated from nature and capable of infecting E. coli type K99 so as to kill the same, as an active ingredient, and a method for preventing and treating E. coli type K99 infections using the said composition. According to the present invention, the bacteriophage EK99P-1, an active ingredient of the composition, has a killing activity against E. coli type K99 and has the genome represented by SEQ. ID. NO: 1.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: December 15, 2015
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seongjun Yoon, Sooyoun Jun, Hyoungrok Paik, Jeesoo Son, Sanghyeon Kang
  • Publication number: 20150322409
    Abstract: The present invention relates to a composition comprising the bacteriophage EK88P-1 isolated from the nature and having a broad antibacterial spectrum against E. coli as an active ingredient, and a method for preventing and treating E. coli infections using the said composition. The bacteriophage EK88P-1, the active ingredient of the composition of the present invention, has a broad antibacterial spectrum against E. coli and has the genome characteristically composed of the partial nucleotide sequences represented by SEQ. ID. NO: 1˜NO: 25, and also characterized by the bacteriophage belonging to the Myoviridae family according to the morphology that is composed of the major structural proteins in the sizes of approximately 49 kDa, 53 kDa, 94 kDa, and 103 kDa.
    Type: Application
    Filed: May 7, 2015
    Publication date: November 12, 2015
    Applicant: iNtRON Biotechnology, Inc.
    Inventors: Seong Jun YOON, Soo Youn Jun, Hyoung Rok Paik, Jee Soo Son, Hye In Jeong, Sang Hyeon Kang
  • Patent number: 9133492
    Abstract: Vectors expressing kanA-kanB-kanK and other kanamycin production-related genes, Streptomyces<i/> species recombinant bacteria transformed with the vectors, a method of producing kanamycin antibiotics by the bacteria, and a new kanamycin compound produced by the bacterium are provided. With the use of the recombinant bacteria of the present invention, the direct fermentative biosynthesis of amikacin and tobramycin as semi-synthetic kanamycins is possible, and the yield of kanamycin B as a precursor of the semi-synthetic kanamycin is improved.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: September 15, 2015
    Assignee: iNtRON Biotechnology, Inc.
    Inventors: Yeo Joon Yoon, Sung Ryeol Park, Je Won Park, Jae Kyung Sohng
  • Patent number: 9121023
    Abstract: The present invention relates to a PCR product cloning vector applicable directly to the cloning of a PCR product. More precisely, the present invention relates to a PCR product cloning vector designed to be effective in use for blue/white colony selection and produced based on the restriction enzyme treatment process to generate non-complementary unpaired single overhang and a method for producing the same. According to the method of the present invention, the PCR product cloning vector designed to be advantageous for blue/white cloning selection can be produced with improved efficiency compared with the convention method.
    Type: Grant
    Filed: October 29, 2008
    Date of Patent: September 1, 2015
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seongjun Yoon, SooYoun Jun, SangHyeon Kang
  • Patent number: 8961935
    Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent coated with carboxylated mannan, particularly a carboxylated mannan coated superparamagnetic MRI contrast agent specifically targeting antigen presenting cells and having excellent in vivo stability, and a method for producing the same. The MRI contrast agent coated with carboxylated mannan of the present invention can provide excellent in vivo stability and biocompatibility owing to its high surface negative charge, and can be introduced specifically into antigen presenting cells owing to mannose of mannan, so as to visualize the antigen presenting cells and the tissue containing the antigen presenting cells in MRI.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: February 24, 2015
    Assignee: Intron Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Sang Hyeon Kang, Yong Yeon Jeong, In Kyu Park, Chong Su Cho, You Kyoung Kim, Won Jong Kim, Ran Namgung
  • Patent number: 8951757
    Abstract: The present invention relates to a method for the preparation of a labeling agent derived from one type of tRNA prepared by in vitro transcription, which is usable for non-radioactive selective labeling of target proteins produced by in vitro translation with fluorophore or biotin; and a method for selective labeling of target proteins produced by in vitro translation using the labeling agent without labeling pre-existing proteins in the reaction mixture.
    Type: Grant
    Filed: January 7, 2009
    Date of Patent: February 10, 2015
    Assignee: Intron Biotechnology, Inc.
    Inventors: Seongjun Yoon, SooYoun Jun, SangHyeon Kang
  • Publication number: 20140377842
    Abstract: The present invention relates to a bacteriophage having bactericidal activity against Actinobacillus pleuropneumoniae. Bacteriophage PA1? can infect Actinobacillus pleuropneumoniae and kill the same bacteria and is characterized by the genome of 34,553 by represented by SEQ ID NO: 1.
    Type: Application
    Filed: March 22, 2012
    Publication date: December 25, 2014
    Applicant: INTRON BIOTECHNOLOGY, INC.
    Inventors: Ji Hoon Kim, Tae Gyu Kim, Seong Jun Yoon, Soo Youn Jun, Sang Hyeon Kang, Jung Min Kim, Shuk Ho Kim
  • Publication number: 20140363401
    Abstract: The present invention relates to a composition comprising STP-1, a bacteriophage isolated from nature, capable of infecting Salmonella Typhimurium so as to kill the same as an active ingredient, and a method for preventing and treating Salmonella Typhimurium infection using the said composition. According to the present invention, the bacteriophage STP-1, an active ingredient of the composition, has a killing activity against Salmonella Typhimurium and has the genome represented by SEQ. ID. NO: 1.
    Type: Application
    Filed: September 9, 2011
    Publication date: December 11, 2014
    Applicant: INTRON BIOTECHNOLOGY, INC
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Dong Hwan Kim, Sang Hyeon Kang
  • Publication number: 20130273635
    Abstract: The present invention relates to a bacteriophage PA1? belonging to family Siphoviridae, characterized that it is capable of killing one or more bacteria strains selected from a group comprising Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus homonis, Shigella sonnei, Listeria monocytogenes and Streptococcus pneumonia, and contains a full-length genome of SEQ ID NO: 1. According to the present invention, the bacteriophage PA1? can be used to kill said bacteria and reduce the same effectively. Also, it can be used to remove biofilms generated by said bacteria. Especially, this bacteriophage is applicable for medical industry, food industry, biotechnology and the like, because it is a sort of virus that kills host bacteria without any adverse effect on human, animals and so on. In addition, this bacteriophage can kill noxious bacteria on target sites or target supports without any problem related with resistance development of bacteria.
    Type: Application
    Filed: April 12, 2012
    Publication date: October 17, 2013
    Applicant: INTRON BIOTECHNOLOGY, INC.
    Inventors: Jung Min Kim, Shuk Ho Kim, Seongjun Yoon, Sooyoun Jun, Sanghyeon Kang
  • Patent number: 8377431
    Abstract: The present invention relates to compositions for removing a biofilm formed by Staphylococcus aureus, comprising a bacteriophage, such as Myoviridae family T4-like phage genus bacteriophage (Accession No: KCTC 11153BP, SAP-1) or Podoviridae family ?29-like virus genus bacteriophage (Accession No: KCTC11154BP, SAP-2), and lytic protein derived therefrom, that destroys the biofilm. Also disclosed are pharmaceutical compositions for the treatment of diseases caused by Staphylococcus aureus capable of forming biofilm.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: February 19, 2013
    Assignee: iNtRON Biotechnology, Inc.
    Inventors: Seongjun Yoon, Yunjaie Choi, Se Yung Lee, Jeesoo Son, Sooyoun Jun, Sanghyeon Kang
  • Patent number: 8377866
    Abstract: The present invention relates to a novel antimicrobial protein derived from bacteriophage having killing activity specific to Staphylococcus aureus, more precisely an antimicrobial protein originated from Podoviridae bacteriophage having killing activity specific to Staphylococcus aureus which is the causing agent of infectious disease in human and animals, a pharmaceutical composition for the prevention and treatment of infectious disease caused by Staphylococcus aureus, an antibiotic and a disinfectant containing the bacteriophage-originated antimicrobial protein as an active ingredient.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: February 19, 2013
    Assignee: Intron Biotechnology, Inc.
    Inventors: Seongjun Yoon, Yunjaie Choi, Seyung Lee, Jeesoo Son, Sooyoun Jun, Sanghyeon Kang
  • Publication number: 20130011369
    Abstract: The present invention relates to a composition comprising bacteriophage SP-1, the bacteriophage capable of destroying Salmonella once being infected in Salmonella, as an active ingredient, and a method for prevention and treatment of Salmonella infection using the same. Bacteriophage SP-1, the active ingredient of the composition of the present invention, characteristically has the killing activity to Salmonella and has the genome represented by SEQ. ID. NO: 1.
    Type: Application
    Filed: July 5, 2011
    Publication date: January 10, 2013
    Applicant: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seongjun Yoon, Sooyoun Jun, Hyoungrok Paik, Gimo Jung, Yoonsik Shin, Sanghyeon Kang
  • Patent number: 8329165
    Abstract: The present invention relates to a composition for the treatment of ballast water containing bacteriophage capable of killing specific target bacteria as an active ingredient in order to eliminate or reduce bacteria including pathogenic bacteria present in ballast water, and a biological treatment method of ballast water.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: December 11, 2012
    Assignee: Intron Biotechnology, Inc.
    Inventors: Seongjun Yoon, Sooyoun Jun, Sanghyeon Kang, Yunjaie Choi, Jeesoo Son
  • Publication number: 20120230919
    Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent coated with carboxylated mannan, particularly a carboxylated mannan coated superparamagnetic MRI contrast agent specifically targeting antigen presenting cells and having excellent in vivo stability, and a method for producing the same. The MRI contrast agent coated with carboxylated mannan of the present invention can provide excellent in vivo stability and biocompatibility owing to its high surface negative charge, and can be introduced specifically into antigen presenting cells owing to mannose of mannan, so as to visualize the antigen presenting cells and the tissue containing the antigen presenting cells in MRI.
    Type: Application
    Filed: April 15, 2011
    Publication date: September 13, 2012
    Applicant: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun YOON, Soo Youn JUN, An Sung KWON, Sang Hyeon KANG, Yong Yeon JEONG, In Kyu PARK, Chong Su CHO, You Kyoung KIM, Won Jong KIM, Ran NAMGUNG
  • Patent number: 8232370
    Abstract: The present invention relates to a novel bacteriophage-originated protein having antimicrobial activity, more precisely an antimicrobial protein originated from lytic bacteriophage having killing activity specific to Staphylococcus aureus which is the causing agent of infectious diseases in human and animals, a pharmaceutical composition for the prevention and treatment of the disease caused by Staphylococcus aureus, an antibiotic and a disinfectant containing the bacteriophage-originated antimicrobial protein as an active ingredient.
    Type: Grant
    Filed: July 27, 2007
    Date of Patent: July 31, 2012
    Assignee: Intron Biotechnology, Inc.
    Inventors: Seongjun Yoon, Sanghyeon Kang, Seabong Kyoung, Yunjaie Choi, Jeesoo Son
  • Patent number: 8071352
    Abstract: The present invention relates to a novel bacteriophage, more precisely a novel bacteriophage having killing activity specific to Staphylococcus aureus which is the causing agent of infectious diseases in human and animals, a pharmaceutical composition for the prevention and treatment of the disease caused by Staphylococcus aureus, an antibiotic and a disinfectant containing the bacteriophage as an active ingredient.
    Type: Grant
    Filed: June 20, 2007
    Date of Patent: December 6, 2011
    Assignee: Intron Biotechnology, Inc.
    Inventors: Seongjun Yoon, Sanghyeon Kang, Seabong Kyoung, Yunjaie Choi, Jeesoo Son
  • Patent number: D690828
    Type: Grant
    Filed: September 17, 2012
    Date of Patent: October 1, 2013
    Assignee: iNtRON Biotechnology, Inc.
    Inventors: Seongjun Yoon, Sanghyeon Kang, Jaegoo Seol